Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

145 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].
Di Cosimo S, Baselga J. Di Cosimo S, et al. Nat Rev Clin Oncol. 2010 Mar;7(3):139-47. doi: 10.1038/nrclinonc.2009.234. Epub 2010 Feb 2. Nat Rev Clin Oncol. 2010. PMID: 20125090 Review.
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.
Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud F, Raspagliesi F, Verzoni E, Di Cosimo S, Locati LD, Cristofanilli M, Daidone MG, Cappelletti V. Reduzzi C, et al. Among authors: di cosimo s. Semin Cancer Biol. 2020 Feb;60:344-350. doi: 10.1016/j.semcancer.2019.10.008. Epub 2019 Oct 15. Semin Cancer Biol. 2020. PMID: 31626958 Review.
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F. Di Cosimo S, et al. Among authors: di nicola m. PLoS One. 2019 Aug 7;14(8):e0220644. doi: 10.1371/journal.pone.0220644. eCollection 2019. PLoS One. 2019. PMID: 31390375 Free PMC article. Clinical Trial.
Huge response to letrozole in inoperable T4 breast cancer: a case report.
Di Cosimo S, Altomare V, Ferretti G, Gravante G, Rabitti C, Rea F, Arullani A, D'Aprile M. Di Cosimo S, et al. Clin Ter. 2001 Jul-Aug;152(4):263-5. Clin Ter. 2001. PMID: 11725620
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Carlini P, Ferretti G, Di Cosimo S, Colella E, Tonachella R, Romiti A, Tomao S, Frassoldati A, Papaldo P, Fabi A, Ruggeri EM, Cognetti F. Carlini P, et al. Among authors: di cosimo s. J Steroid Biochem Mol Biol. 2003 Jul;86(1):107-9. doi: 10.1016/s0960-0760(03)00249-8. J Steroid Biochem Mol Biol. 2003. PMID: 12943750 Clinical Trial.
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Papaldo P, et al. Among authors: di cosimo s, di lauro l. J Clin Oncol. 2003 Sep 15;21(18):3462-8. doi: 10.1200/JCO.2003.03.034. J Clin Oncol. 2003. PMID: 12972521 Clinical Trial.
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
Ferretti G, Di Cosimo S, Giannarelli D, Carlini P, Papaldo P, Alimonti A, Fabi A, Mandalà M, Milella M, Ruggeri EM, Cognetti F. Ferretti G, et al. Among authors: di cosimo s. J Clin Oncol. 2004 Feb 1;22(3):568-9. doi: 10.1200/JCO.2004.99.085. J Clin Oncol. 2004. PMID: 14752083 No abstract available.
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.
Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F. Di Cosimo S, et al. Ann Oncol. 2004 Jul;15(7):1065-71. doi: 10.1093/annonc/mdh266. Ann Oncol. 2004. PMID: 15205200
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
Fabi A, Papaldo P, Pino MS, Ferretti G, Carlini P, Pacetti U, Di Cosimo S, Nardoni C, Giannarelli D, Sacchi I, Cognetti F. Fabi A, et al. Among authors: di cosimo s. Anticancer Res. 2004 May-Jun;24(3b):1963-7. Anticancer Res. 2004. PMID: 15274385 Clinical Trial.
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J. Matar P, et al. Among authors: di cosimo s. Clin Cancer Res. 2004 Oct 1;10(19):6487-501. doi: 10.1158/1078-0432.CCR-04-0870. Clin Cancer Res. 2004. PMID: 15475436
145 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback